- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/4192 - 1,2,3-Triazoles
Patent holdings for IPC class A61K 31/4192
Total number of patents in this class: 1746
10-year publication summary
|
121
|
117
|
130
|
136
|
131
|
123
|
140
|
108
|
119
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 517 |
29 |
| Bristol-myers Squibb Company | 4886 |
27 |
| Achillion Pharmaceuticals, Inc. | 169 |
25 |
| F. Hoffmann-La Roche AG | 7942 |
24 |
| GW Research Limited | 360 |
23 |
| Board of Regents, The University of Texas System | 5604 |
21 |
| Idorsia Pharmaceuticals Ltd. | 362 |
20 |
| Merck Sharp & Dohme LLC | 3742 |
20 |
| Novartis AG | 11297 |
18 |
| Merck Patent GmbH | 5849 |
18 |
| The Regents of the University of California | 19479 |
17 |
| Gilead Sciences, Inc. | 1949 |
17 |
| Hoffmann-La Roche Inc. | 3252 |
15 |
| Boehringer Ingelheim International GmbH | 4762 |
15 |
| Centre National de La Recherche Scientifique | 10052 |
14 |
| University of Tennessee Research Foundation | 745 |
14 |
| Emory University | 1588 |
13 |
| Merck Sharp & Dohme Corp. | 2218 |
12 |
| The Scripps Research Institute | 1353 |
12 |
| Takeda Pharmaceutical Company Limited | 2945 |
11 |
| Other owners | 1381 |